Cargando…

c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer

Pancreatic cancer ranks fourth among cancer-related deaths, with a 5-years overall survival rate being below 10%. Gemcitabine (dFdC) has been considered the first-line drug for patients with pancreatic cancer. However, the clinical effectiveness is less than 20% due to drug resistance. Most importan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Jingjing, Huang, Min, Shen, Qinghong, Ding, Ming, Yu, Shaofang, Guo, Yajuan, Lin, Yuefang, Zheng, Yaqiu, Chen, Wenbo, Yan, Wenxin, Liu, Zhongqiu, Wang, Dawei, Hu, Ming, Lu, Linlin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108354/ https://www.ncbi.nlm.nih.gov/pubmed/35586061 http://dx.doi.org/10.3389/fphar.2022.851512

Ejemplares similares

Bile acids promote the development of HCC by activating inflammasome
por: Chen, Wenbo, et al.
Publicado: (2023)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma
por: Xiao, Zhijun, et al.
Publicado: (2021)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Wogonin increases gemcitabine sensitivity in pancreatic cancer by inhibiting Akt pathway
por: Zhang, Tianli, et al.
Publicado: (2022)

Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer
por: Chen, Xi, et al.
Publicado: (2022)

Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
por: Miao, Xin, et al.
Publicado: (2016)

Integrating Network Pharmacology and Experimental Validation to Investigate the Effects and Mechanism of Astragalus Flavonoids Against Hepatic Fibrosis
por: An, Lin, et al.
Publicado: (2021)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

Trametinib Inhibits the Growth and Aerobic Glycolysis of Glioma Cells by Targeting the PKM2/c-Myc Axis
por: Gao, Mingjun, et al.
Publicado: (2021)

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancer
por: Hou, Zelin, et al.
Publicado: (2023)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis
por: Zhang, Meiling, et al.
Publicado: (2021)

Thymoquinone affects the gemcitabine sensitivity of pancreatic cancer by regulating collagen via hypoxia inducible factor-1α
por: Zhao, Zhanxue, et al.
Publicado: (2023)

Novel Gemcitabine-Re(I) Bisquinolinyl Complex Combinations and Formulations With Liquid Crystalline Nanoparticles for Pancreatic Cancer Photodynamic Therapy
por: Liew, Hui Shan, et al.
Publicado: (2022)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications
por: Guo, Libin, et al.
Publicado: (2022)

Gypenosides Attenuate Pulmonary Fibrosis by Inhibiting the AKT/mTOR/c-Myc Pathway
por: Liu, Suqing, et al.
Publicado: (2022)

KIF20A is associated with clinical prognosis and synergistic effect of gemcitabine combined with ferroptosis inducer in lung adenocarcinoma
por: He, Hua, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Xinbao Pill in Chronic Heart Failure
por: Wang, Yuanping, et al.
Publicado: (2022)

Uncovering the Effect and Mechanism of Rhizoma Corydalis on Myocardial Infarction Through an Integrated Network Pharmacology Approach and Experimental Verification
por: Li, Jingyan, et al.
Publicado: (2022)

Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1
por: Pan, Xiaohui, et al.
Publicado: (2021)

β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
por: Cao, Zhang-qi, et al.
Publicado: (2019)

The association of four genetic variants with myelosuppression in gemcitabine‐treated Japanese is not evident in gemcitabine/carboplatin‐treated Swedes
por: Björn, Niclas, et al.
Publicado: (2022)

Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
por: Tang, Qiyu, et al.
Publicado: (2023)

Silencing c-Myc Enhances the Antitumor Activity of Bufalin by Suppressing the HIF-1α/SDF-1/CXCR4 Pathway in Pancreatic Cancer Cells
por: Liu, Xia, et al.
Publicado: (2020)

miR-7/TGF-β2 axis sustains acidic tumor microenvironment-induced lung cancer metastasis
por: Su, Tao, et al.
Publicado: (2022)

The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer
por: Jia, Yanfei, et al.
Publicado: (2018)

Efficacy of Xinbao pill on chronic heart failure: Study protocol of a multicenter, randomized, double-blind, placebo-controlled trial
por: Wang, Yuanping, et al.
Publicado: (2022)

Corrigendum: β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-Pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
por: Cao, Zhang-qi, et al.
Publicado: (2020)

Wogonin induces ferroptosis in pancreatic cancer cells by inhibiting the Nrf2/GPX4 axis
por: Liu, Xing, et al.
Publicado: (2023)

miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis
por: Yang, Rui-Meng, et al.
Publicado: (2017)

The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
por: Kou, Wen, et al.
Publicado: (2022)

1,2,3,4,6-Penta-O-Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression
por: Tseeleesuren, Duurenjargal, et al.
Publicado: (2018)

Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy
por: Zhou, Yihui, et al.
Publicado: (2021)

Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells
por: Lin, Lanke, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis
por: Pelengaris, Stella, et al.
Publicado: (2004)

Prevention of Wogonin on Colorectal Cancer Tumorigenesis by Regulating p53 Nuclear Translocation
por: Feng, Qian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5rmp4cs8fod2j50004dn3m15ck